NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
(Total Views: 122)
Posted On: 09/27/2018 5:27:55 PM
NetworkNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) CEO Presents Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer
BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Wednesday announced that it achieved proof of concept in the Phase IIa study of its lead clinical candidate, Bria-IMT(Trademarked), in advanced breast cancer. The company followed the after-hours news with a live webcast discussing the results, as presented by the company’s CEO Dr. Bill Williams.
The data demonstrates promising anti-tumor activity of Bria-IMT in heavily pre-treated advanced breast cancer patients. BriaCell is now focusing on the combination study of Bria-IMT with pembrolizumab (Keytruda®, manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy®, manufactured by Bristol-Myers Squibb Company) in patients with advanced breast cancer.
“Bria-IMT appears to be most effective in patients who match with Bria-IMT at 2 HLA loci (types) further supporting BriaCell’s HLA Matching Hypothesis, and the development of Bria-OTS to cover 90% of the patient population. We are delighted with these positive clinical findings that confirm our HLA Matching Hypothesis in the Phase I/IIa trial in advanced breast cancer showing significant tumor shrinkage without serious side effects,” Dr. Williams stated in the press release. “We believe that combination studies with immune checkpoint inhibitors should create even more potent anti-cancer immune responses, leading to our strategy of combination studies of Bria-IMT with Keytruda® or Yervoy®.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Wednesday announced that it achieved proof of concept in the Phase IIa study of its lead clinical candidate, Bria-IMT(Trademarked), in advanced breast cancer. The company followed the after-hours news with a live webcast discussing the results, as presented by the company’s CEO Dr. Bill Williams.
The data demonstrates promising anti-tumor activity of Bria-IMT in heavily pre-treated advanced breast cancer patients. BriaCell is now focusing on the combination study of Bria-IMT with pembrolizumab (Keytruda®, manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy®, manufactured by Bristol-Myers Squibb Company) in patients with advanced breast cancer.
“Bria-IMT appears to be most effective in patients who match with Bria-IMT at 2 HLA loci (types) further supporting BriaCell’s HLA Matching Hypothesis, and the development of Bria-OTS to cover 90% of the patient population. We are delighted with these positive clinical findings that confirm our HLA Matching Hypothesis in the Phase I/IIa trial in advanced breast cancer showing significant tumor shrinkage without serious side effects,” Dr. Williams stated in the press release. “We believe that combination studies with immune checkpoint inhibitors should create even more potent anti-cancer immune responses, leading to our strategy of combination studies of Bria-IMT with Keytruda® or Yervoy®.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)